Press Releases AdAlta Limited

Equities

Market Closed - Australian S.E. Other stock markets 07:10:47 10/05/2024 BST			5-day change	1st Jan Change
0.023 ^AUD	0.00%		-14.81%	-4.17%

04-29	AdAlta Secures Up to AU$3.7 Million for MOU, i-body Programs	MT
04-08	AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market	MT

AdAlta delivers positive Phase I Extension Study results for AD-214	03-08	AQ
AdAlta closes oversubscribed $1.65 million raise	11-08	AQ
AdAlta making material progress on partnering talks	23/10/23	AQ
AdAlta says new AD-214 dosing models enhance partnering potential	26/09/23	AQ
AdAlta completes enrolment for AD-214 fibrosis safety trial	21/09/23	AQ
AdAlta to Present at August 24th Virtual Investor Summit	16/08/23	NE
AdAlta back in the clinic with AD-214	07/08/23	AQ
AdAlta eyes AD-214 Phase I extension study	18/07/23	AQ
AdAlta links AD-214 results with efficacy thanks to new data	07/07/23	AQ
AdAlta extends I-body trial following ethics approval	29/06/23	AQ
AdAlta to present at June 1 Virtual Investor Summit	30/05/23	NE
AdAlta secures A$1.28 million in rights offer to advance AD-214	25/05/23	AQ
AdAlta to support early return to clinical trials of AD-214 with rights offer	01/05/23	AQ
AdAlta CEO highlights strong progress across CAR-T and AD-214 programs	28/02/23	AQ
AdAlta welcomes long-term support from Yuuwa Capital investors	17/02/23	AQ
AdAlta : Company Presentation	24/07/22	PU
AdAlta : Quarterly Appendix 4C and Activities Report	24/07/22	PU
AdAlta : Quarterly Appendix 4C and Activities Report	04/04/22	PU
AdAlta : PAC Partners Healthcare Conference - Corporate Presentation	04/04/22	PU
AdAlta : Notification regarding unquoted securities - 1AD	04/04/22	PU

No results for this search